Evaluation of Physician-based Decision Support
Evaluation of Physician-based Decision Support in Patients With Type 1 Diabetes on Multiple Daily Injection Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of type 1 diabetes mellitus for at least 1 year.
- Male or female subjects 18 to 50 years of age.
- Physically willing and able to perform 30 min of exercise (as determined by the investigator after reviewing the subject's activity level).
- Use of multiple daily insulin injections (MDI).
- A1C ≥7.0% at the time of screening.
- Current use of a smart phone.
- Willingness to follow all study procedures, including attending all clinic visits.
- Willingness to sign informed consent and HIPAA documents.
Exclusion Criteria:
- Female of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
- Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial infarction, angina pectoris, or coronary arterial bypass graft or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological arrhythmia judged by the investigator to be exclusionary.
- Renal insufficiency (GFR < 60 ml/min, using the MDRD equation as reported by the OHSU laboratory).
- Liver failure, cirrhosis, or any other liver disease that compromises liver function as determined by the investigator.
- Hematocrit of less than 36% for men, less than 32% for women.
- History of severe hypoglycemia during the past 12 months prior to screening visit or hypoglycemia unawareness as judged by the investigator. Subjects will complete a hypoglycemia awareness questionnaire. Subjects will be excluded for four or more R responses.
- Adrenal insufficiency.
- Any active infection.
- Known or suspected abuse of alcohol, narcotics, or illicit drugs.
- Seizure disorder.
- Active foot ulceration.
- Peripheral arterial disease.
- Major surgical operation within 30 days prior to screening.
- Use of an investigational drug within 30 days prior to screening.
- Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus).
- Bleeding disorder or platelet count below 50,000.
- Allergy to aspart or glargine insulin.
- Need for uninterrupted treatment of acetaminophen.
- Current administration of oral or parenteral corticosteroids.
- Any life threatening disease, including malignant neoplasms and medical history of malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).
- Beta blockers or non-dihydropyridine calcium channel blockers.
- Current use of any medication intended to lower glucose other than insulin (ex. use of liraglutide).
- A positive response to any of the questions from the Physical Activity Readiness Questionnaire with one exception: subject will not be excluded if he/she takes a single blood pressure medication that doesn't impact heart rate and blood pressure is controlled on the medication (blood pressure is less than 140/90 mmHg).
- Any chest discomfort with physical activity, including pain or pressure, or other types of discomfort.
- Any clinically significant disease or disorder which in the opinion of the Investigator may jeopardize the subject's safety or compliance with the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Aerobic exercise
Subjects in this arm will complete aerobic exercise at home and at OHSU for the study.
Subjects will use a Dexcom G6 CGM.
|
Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
|
|
Experimental: Anaerobic exercise
Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study.
Subjects will use a Dexcom G6 CGM.
|
Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
|
|
Experimental: High intensity interval exercise
Subjects in this arm will complete high intensity interval exercise at home and at OHSU for the study.
Subjects will use a Dexcom G6 CGM.
|
Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of Time With Sensed Glucose 70-180 mg/dl
Time Frame: Days 1-7
|
Assess the percent of time that the Dexcom G6 reported sensor glucose values between 70-180 mg/dl using values uploaded to Dexcom Clarity.
The percent of time with sensed glucose 70-180 mg/dl was averaged across days 1-7.
|
Days 1-7
|
|
Percent of Time With Sensed Glucose Less Than 70 mg/dl
Time Frame: Days 1-7
|
Assess the percent of time that the Dexcom G6 reported sensor glucose values less than 70 mg/dl using values uploaded to Dexcom Clarity.The percent of time with sensed glucose less than 70 mg/dl was averaged across days 1-7.
|
Days 1-7
|
|
Percent of Time With Sensed Glucose 70-180 mg/dl
Time Frame: Days 22-28
|
Assess the percent of time that the Dexcom G6 reported sensor glucose values between 70-180 mg/dl using values uploaded to Dexcom Clarity.The percent of time with sensed glucose 70-180 mg/dl was averaged across days 22-28.
|
Days 22-28
|
|
Percent of Time With Sensed Glucose Less Than 70 mg/dl
Time Frame: Days 22-28
|
Assess the percent of time that the Dexcom G6 reported sensor glucose values less than 70 mg/dl using values uploaded to Dexcom Clarity.The percent of time with sensed glucose less then 70 mg/dl was averaged across days 22-28.
|
Days 22-28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of Time With Sensed Glucose Less Than 54 mg/dl
Time Frame: Days 1-7
|
Assess the percent of time that the Dexcom G6 reported sensor glucose values less than 54 mg/dl using values uploaded to Dexcom Clarity.The percent of time with sensed glucose less then 54 mg/dl was averaged across days 1-7.
|
Days 1-7
|
|
Mean Sensed Glucose
Time Frame: Days 1-7
|
Assess the mean Dexcom G6 reported sensor glucose values using values uploaded to Dexcom Clarity.The mean sensed glucose was averaged across days 1-7.
|
Days 1-7
|
|
Percent of Time With Sensed Glucose Less Than 54 mg/dl
Time Frame: Days 22-28
|
Assess the percent of time that the Dexcom G6 reported sensor glucose values less than 54 mg/dl using values uploaded to Dexcom Clarity.The percent of time with sensed glucose less then 54 mg/dl was averaged across days 22-28.
|
Days 22-28
|
|
Mean Sensed Glucose
Time Frame: Days 22-28
|
Assess the mean Dexcom G6 reported sensor glucose values using values uploaded to Dexcom Clarity.The mean sensed glucose was averaged across days 22-28.
|
Days 22-28
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 18023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exercise
-
NCT07164911RecruitingExercise Training | Cardiac Rehabilitation | Exercise Intolerance | Exercise Intervention | Exercise Adaptations | HFrEF - Heart Failure With Reduced Ejection Fraction
-
NCT07618455CompletedExercise Physiology | Exercise Immunology
-
NCT07157150CompletedExercise Training | Exercise Physiology
-
NCT05090501CompletedGreen Exercise | Indoor Exercise
-
NCT06672952RecruitingCognitive Function | Blood Flow | Nitric Oxide | Endurance Exercise | Exercise Performance | Exercise Recovery
-
NCT06616428CompletedAgeing | Aerobic Exercise | Resistance Exercise | Combined Exercise
-
NCT07565168CompletedEndurance Exercise | Running Performance | Exercise Physiology
-
NCT07492446CompletedExercise Ergogenics | Recovery Methods | Carnitine Ingestion | Exercise Fatigue | Exercise and Recovery
-
NCT01738984CompletedMomZing Exercise Videos Online | Standard Exercise DVD
Clinical Trials on Dexcom G6 CGM
-
NCT05641792Not yet recruitingHyperglycemia | Infections | Hypoglycemia | Surgical Site Infection | Peritonitis
-
NCT05351190Enrolling by invitationType 2 Diabetes
-
NCT03772600CompletedType 1 Diabetes Mellitus
-
NCT05439928Completed
-
NCT06483945Recruiting
-
NCT03805412CompletedObesity | Diabetes Mellitus, Type 2 | PreDiabetes
-
NCT05741489CompletedEnd Stage Kidney Disease
-
NCT05067075CompletedGestational Diabetes Mellitus in Pregnancy
-
NCT04845685Suspended
-
NCT05678712CompletedType1diabetes | Hemodialysis | Type2Diabetes